These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 8200934)

  • 21. Androgen secretion in ectopic ACTH syndrome and in Cushing's disease: modifications before and after surgery.
    Barbetta L; Dall'Asta C; Re T; Colombo P; Travaglini P; Ambrosi B
    Horm Metab Res; 2001 Oct; 33(10):596-601. PubMed ID: 11607879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to vasopressin action on the kidney in patients with Cushing's disease.
    Knoepfelmacher M; Pradal MJ; Dio RD; Salgado LR; Semer M; Wajchenberg BL; Liberman B
    Eur J Endocrinol; 1997 Aug; 137(2):162-6. PubMed ID: 9272104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased autonomic modulation of heart rate and altered cardiac sympathovagal balance in patients with Cushing's syndrome: role of endogenous hypercortisolism.
    Chandran DS; Ali N; Jaryal AK; Jyotsna VP; Deepak KK
    Neuroendocrinology; 2013; 97(4):309-17. PubMed ID: 23327928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin secretion, insulin sensitivity and glucose-mediated glucose disposal in Cushing's disease: a minimal model analysis.
    Page R; Boolell M; Kalfas A; Sawyer S; Pestell R; Ward G; Alford F
    Clin Endocrinol (Oxf); 1991 Dec; 35(6):509-17. PubMed ID: 1769133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of pulsatile human corticotropin-releasing hormone administration on the adrenal insufficiency that follows cure of Cushing's disease.
    Avgerinos PC; Nieman LK; Oldfield EH; Loughlin T; Barnes KM; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1989 May; 68(5):912-6. PubMed ID: 2541160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: potential clinical implications.
    Kling MA; Roy A; Doran AR; Calabrese JR; Rubinow DR; Whitfield HJ; May C; Post RM; Chrousos GP; Gold PW
    J Clin Endocrinol Metab; 1991 Feb; 72(2):260-71. PubMed ID: 1846869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adrenal incidentaloma: a new cause of the metabolic syndrome?
    Terzolo M; Pia A; Alì A; Osella G; Reimondo G; Bovio S; Daffara F; Procopio M; Paccotti P; Borretta G; Angeli A
    J Clin Endocrinol Metab; 2002 Mar; 87(3):998-1003. PubMed ID: 11889151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma levels of atrial natriuretic hormone in Cushing's syndrome.
    Yamaji T; Ishibashi M; Yamada A; Takaku F; Itabashi A; Katayama S; Ishii J; Takami M; Fukushima T
    J Clin Endocrinol Metab; 1988 Aug; 67(2):348-52. PubMed ID: 2969001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance.
    Atkinson AB; Kennedy A; Wiggam MI; McCance DR; Sheridan B
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):549-59. PubMed ID: 16268808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FK 33-824, a met-enkephalin analog, blocks corticotropin-releasing hormone-induced adrenocorticotropin secretion in normal subjects but not in patients with Cushing's disease.
    Allolio B; Deuss U; Kaulen D; Leonhardt U; Kallabis D; Hamel E; Winkelmann W
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1427-31. PubMed ID: 3023423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melatonin secretion and non-specific immune responses are differentially expressed in corticotropin-dependent and corticotropin-independent Cushing's syndrome.
    Tomova A; Kumanov P; Robeva R; Manchev S; Konakchieva R
    Med Sci Monit; 2008 Jun; 14(6):CR327-332. PubMed ID: 18509277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission.
    Giordano R; Picu A; Marinazzo E; D'Angelo V; Berardelli R; Karamouzis I; Forno D; Zinnà D; Maccario M; Ghigo E; Arvat E
    Clin Endocrinol (Oxf); 2011 Sep; 75(3):354-60. PubMed ID: 21521323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormonal and metabolic rhythms in Cushing's syndrome.
    Johnston DG; Alberti KG; Nattrass M; Barnes AJ; Bloom SR; Joplin GF
    Metabolism; 1980 Oct; 29(11):1046-52. PubMed ID: 7001175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The nocturnal serum thyrotropin surge is abolished in patients with adrenocorticotropin (ACTH)-dependent or ACTH-independent Cushing's syndrome.
    Bartalena L; Martino E; Petrini L; Velluzzi F; Loviselli A; Grasso L; Mammoli C; Pinchera A
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1195-9. PubMed ID: 1851180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome.
    Reincke M; Nieke J; Krestin GP; Saeger W; Allolio B; Winkelmann W
    J Clin Endocrinol Metab; 1992 Sep; 75(3):826-32. PubMed ID: 1517373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.
    Aron DC; Raff H; Findling JW
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1780-5. PubMed ID: 9177382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of hypercortisolism on development of atherosclerotic changes in blood vessels].
    Jezková J; Marek J; Prázný M; Krsek M; Malícková K; Rosická M; Jarkovská Z; Pecen L
    Vnitr Lek; 2003 Aug; 49(8):656-67. PubMed ID: 14518092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leucine metabolism in patients with Cushing's syndrome before and after successful treatment.
    Bowes SB; Benn JJ; Scobie IN; Umpleby AM; Lowy C; Sönksen PH
    Clin Endocrinol (Oxf); 1993 Nov; 39(5):591-8. PubMed ID: 8252750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of serum leptin levels in Cushing's syndrome.
    Widjaja A; Schürmeyer TH; Von zur Mühlen A; Brabant G
    J Clin Endocrinol Metab; 1998 Feb; 83(2):600-3. PubMed ID: 9467580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.